Company news from the 05/23/06 News Brief

Share this article:
Novavax announced Friday that it has entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD). Under terms of the agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of predetermined clinical and regulatory milestones, as well as royalties on all net sales of the product. Esprit will be responsible for all development costs and will lead clinical programs. Novavax will be responsible for manufacturing the product in its existing facility, located in Philadelphia.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.